Ars Pharmaceuticals Inc (SPRY)
$14
+0.62
(+4.63%)▲
Performance
- $13.26$14.03$14.00
5.29%
Downside
Day's Volatility :5.49%
Upside
0.21%
- $4.65$18.51$14.00
66.77%
Downside
52 Weeks Volatility :74.86%
Upside
24.37%
Returns
| Period | Ars Pharmaceuticals Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 4.45% | 0.0% |
6 Months | 49.83% | 0.0% |
1 Year | 182.88% | 0.0% |
3 Years | 82.79% | -24.1% |
Highlights
Market Capitalization | 1.3B |
Book Value | $2.07 |
Earnings Per Share (EPS) | -0.5 |
Wall Street Target Price | 26.5 |
Profit Margin | 0.0% |
Operating Margin TTM | -1051.64% |
Return On Assets TTM | -16.23% |
Return On Equity TTM | -22.41% |
Revenue TTM | 2.6M |
Revenue Per Share TTM | 0.03 |
Quarterly Revenue Growth YOY | 4900.0% |
Gross Profit TTM | 1.3M |
EBITDA | -60.4M |
Diluted Eps TTM | -0.5 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.43 |
EPS Estimate Next Year | -0.42 |
EPS Estimate Current Quarter | -0.15 |
EPS Estimate Next Quarter | -0.25 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 89.29%
Technicals Summary
Sell
Neutral
Buy
Ars Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Ars Pharmaceuticals Inc | -20.31% | 49.83% | 182.88% | 82.79% | -46.48% |
 Regeneron Pharmaceuticals, Inc. | -22.64% | -24.32% | -6.91% | 15.67% | 106.43% |
 Biontech Se | -2.39% | 5.8% | 10.48% | -66.36% | 407.41% |
 Alnylam Pharmaceuticals, Inc. | -16.76% | 63.55% | 51.52% | 31.97% | 130.85% |
 Vertex Pharmaceuticals Incorporated | -5.17% | 0.63% | 27.5% | 148.14% | 106.59% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Ars Pharmaceuticals Inc | NA | NA | NA | -0.43 | -0.22 | -0.16 | NA | 2.07 |
Regeneron Pharmaceuticals, Inc. | 18.38 | 18.38 | 1.11 | 44.91 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -3.04 | -0.02 | -0.01 | NA | 79.73 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -0.17 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.18 | 0.54 | -0.03 | 0.12 | NA | 60.65 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Ars Pharmaceuticals Inc | Buy | $1.3B | -46.48% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $81.7B | 106.43% | 18.38 | 33.61% |
Biontech Se | Buy | $24.5B | 407.41% | 160.8 | -15.36% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.1B | 130.85% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $116.2B | 106.59% | 32.84 | -4.51% |
Insights on Ars Pharmaceuticals Inc
Increasing Revenue
Revenue is up for the last 3 quarters, -30.0K → 568.0K (in $), with an average increase of 59.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 4 quarters, -7.16M → -19.12M (in $), with an average decrease of 39.3% per quarter
Institutional Holdings
Deerfield Management Co
11.40%RA Capital Management, LLC
11.18%Orbimed Advisors, LLC
9.51%BlackRock Inc
4.20%SR ONE CAPITAL MANAGEMENT, LP
4.13%Vanguard Group Inc
3.45%
Company Information
silverback therapeutics is a biotechnology company that was founded in 2016. the company is based in seattle, wa and is funded by orbimed.
Organization | Ars Pharmaceuticals Inc |
Employees | 24 |
CEO | Mr. Richard Lowenthal M.B.A., M.S., MSMSEL |
Industry | Healthcare |
